Advancing antimicrobial therapies worldwide through outstanding science
North Liberty, Iowa
Joined July 2014
- Tweets755
- Following962
- Followers384
- Likes273
JMI Laboratories retweeted
"The potent in vitro activity of sulopenem against this large collection of recent Enterobacterales and anaerobic clinical isolates from various infection types support its further clinical evaluation to treat IAIs and UTIs"
doi.org/10.1093/jac/dkad099
@jmilabs #OpenAccess #JACNews
#ECCMID2023 might have ended, but you can still access our posters on our website:
jmilabs.com/?pub_filter_type…
JMI Laboratories retweeted
🤝 We are entering into a 6-year collaboration with @jmilabs to undertake to evaluate the performance and increasing potential of rapid and innovative microbiology diagnostics as important tools in the battle against #AMR.
Read more: biomerieux.com/corp/en/who-w…
@ElementTesting
JMI Laboratories retweeted
Congratulations to our team at @jmilabs who are partnering with @biomerieux to fight #antimicrobial resistance. 🦠
Read more here: element.com/about-element/ne…
Interesting!
New Wound Dressing Reveals Infection
#Sweden
miragenews.com/new-wound-dre…
JMI Laboratories retweeted
The process of naming bacteria follows specific rules – but do you know what they are? Fun Friday read from @IDTransmission
ow.ly/hxns50NmFoP
#infectiousdiseases #pathology #microbiology #scicomms #IDTwitter
JMI Laboratories retweeted
“Aztreonam/avibactam activity was not adversely affected by clinically relevant CPEs. Our results support aztreonam/avibactam development to treat infections caused by CRE, including MBL producers”
doi.org/10.1093/jacamr/dlad0…
@jmilabs @heliosader #JACAMRNews
JMI Laboratories retweeted
Just discovered the @jmilabs SENTRY database’s public-facing page (late to the party, I know).
This is SO COOL for looking at resistance rates/patterns! Can also do granular queries for specific genes/phenotypes/bugs/etc.
sentry-mvp.jmilabs.com
In Q1 2023, we published 12 peer-review articles.
Read them here: jmilabs.com/?pub_filter_type…
Have you reviewed the late 2022 @WHO's fungal priority pathogens list? who.int/publications/i/item/…
.@AMAManual, do you have an official designation for which countries fall into Eastern vs. Western Europe? And, if so, how was this divided? By WHO regulations or something else?
Drug-resistant fungal infections increased according to @sciam: scientificamerican.com/artic…
Congratulations to @MundipharmaTalk on their FDA approval for rezafungin (rezzayo)!
fda.gov/drugs/new-drugs-fda-…
JMI Laboratories retweeted
Over 800 registrations! 🤩
Many thanks to all the participants for this amazing webinar.
Recording now available 👇
revive.gardp.org/susceptibil…
@jmilabs @RafaMCanton @microRyC
#antibacterialdrug #webinar
JMI Laboratories retweeted
Fellows in-training, residents and medical students are invited to present cases at #IDWeek2023. Selected cases will be featured in Fellows’ Day workshops, and travel grants up to $800 are available to cover expenses.
Submit your case by May 3: idweek.org/presenters/
We're happy to share the completion of our 2022 SENTRY Antimicrobial Surveillance Testing!
ALT SENTRY Numbers 2018-2022
JMI Laboratories retweeted
Incredibly informative report from the team at @jmilabs on longitudinal (2016-2020) resistance patterns in E. coli and K. pneumo.
Lots of pertinent info but a few things that stood out:
Link: academic.oup.com/ofid/articl…
JMI Laboratories retweeted
📅 2 March 2023
That's the date of our next REVIVE webinar! 🤩
Together with Dee Shortridge @jmilabs and Rafael Canton @microRyC we will discuss susceptibility testing in antibacterial drug R&D.
Register now: attendee.gotowebinar.com/reg…
JMI Laboratories retweeted
Registration is open for our next REVIVE webinar! 🤗
We'll discuss "Susceptibility testing in #antibacterial drug R&D" with Dee Shortridge @jmilabs and Rafael Canton @microRyC
Make sure to join! 👇👇
Register now: attendee.gotowebinar.com/reg…
